You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 12,090,148

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,090,148

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
Inventor(s):	Joel Trugman, Michelle Finnegan
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US17/389,223
Patent Claims:	1. A method for the preventive treatment of migraine in a patient having migraine headaches, the method comprising administering to the patient 60 mg atogepant, or a pharmaceutically acceptable salt thereof, once daily for more than 12 weeks; wherein administration of atogepant is associated with a reduction in mean monthly migraine days, and wherein administration of atogepant is associated with a reduction from baseline in body weight. 2. The method of claim 1, wherein administration of atogepant results in a reduction in mean monthly migraine days of at least about 3.6 days. 3. The method of claim 1, wherein administration of atogepant results in a reduction in mean monthly migraine days of at least about 3.8 days. 4. The method of claim 1, wherein administration of atogepant results in a reduction in mean monthly migraine days of at least about 4.2 days. 5. The method of claim 1, wherein administration of atogepant results in at least 50% reduction in monthly migraine days. 6. The method of claim 1, wherein administration of atogepant results in a reduction in body weight from baseline of at least about 0.5 kg. 7. The method of claim 1, wherein administration of atogepant results in a reduction in body weight from baseline of at least about 0.8 kg. 8. The method of claim 1, wherein administration of atogepant results in a reduction in body weight from baseline of at least about 1.4 kg. 9. The method of claim 1, wherein at least about 22% of patients achieve a weight decrease of greater than about 5% relative to baseline. 10. The method of claim 1, wherein at least about 4.9% of patients achieve a weight loss of greater than 7% relative to baseline body weight.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.